Literature DB >> 12552493

Fractional excretion of IgG predicts renal outcome and response to therapy in primary focal segmental glomerulosclerosis: a pilot study.

Claudio Bazzi1, Concetta Petrini, Virginia Rizza, Pietro Napodano, Maria Paparella, Girolamo Arrigo, Lucia Pisano, Giuseppe D'Amico.   

Abstract

BACKGROUND: Prolonged treatment with steroids and/or cyclophosphamide improves the prognosis of primary focal segmental glomerulosclerosis (FSGS). In nephrotic patients, no clinical or histological feature predicts responsiveness to therapy.
METHODS: In 50 patients with FSGS, fractional excretion (FE) of immunoglobulin G (IgG), albumin, transferrin, and alpha(1)-microglobulin (alpha(1)m) was calculated. The aim of the study is to assess whether FE IgG and FE alpha(1)m: (1) correlate with histological lesions, (2) predict outcome, and (3) may be useful to guide therapy.
RESULTS: The association of FE IgG with percentage of glomeruli with segmental sclerosis was at the limit of significance (P = 0.01). FE alpha(1)m was associated with extent of tubulointerstitial damage (P = 0.008). By multiple regression analysis, FE alpha(1)m was dependent on FE IgG (R(2) = 0.76; P = 0.000). The predictive value of proteinuric variables on outcome was evaluated in 29 patients with nephrotic syndrome and baseline normal renal function (serum creatinine level, 1.04 +/- 0.22 mg/dL [92 +/- 19 micromol/L]; follow-up, 50 +/- 33 months); remission rates were 91% and 0% in patients with FE IgG less than versus greater than 0.140 (P = 0.0009). By multiple logistic regression analysis, only FE IgG was associated with remission (P = 0.043). Proteinuria less than versus greater than 7.5 g/d of protein predicted end-stage renal failure (0% versus 36%; P = 0.004); the predictive value of FE IgG less than versus greater than 0.140 was higher (0% versus 71%; P = 0.0000). Patients with FE IgG less than 0.025 were responsive to steroids alone (70%) or steroids and cyclophosphamide (20%); patients with FE IgG greater than 0.025 and less than 0.140 were responsive to steroids alone (20%) or steroids and cyclophosphamide (80%); and 100% of patients with FE IgG greater than 0.140 were unresponsive to therapy (P = 0.000).
CONCLUSION: In FSGS, FE IgG is at the limit of statistically significant association with segmental sclerosis, and FE alpha(1)m is associated with extent of tubulointerstitial damage. FE IgG shows the best predictive value for remission, progression, and response to therapy and may be useful to guide treatment. Am J Kidney Dis 41:328-335. Copyright 2003 by the National Kidney Foundation, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552493     DOI: 10.1053/ajkd.2003.50040

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  6 in total

1.  In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.

Authors:  Claudio Bazzi; Virginia Rizza; Sara Raimondi; Daniela Casellato; Pietro Napodano; Giuseppe D'Amico
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

2.  Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study.

Authors:  Maria V Irazabal; Alfonso Eirin; John Lieske; Laurence H Beck; Sanjeev Sethi; Timothy M Borland; John J Dillon; Patrick H Nachman; Samih H Nasr; Lynn D Cornell; Nelson Leung; Daniel C Cattran; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2012-09-17       Impact factor: 5.992

Review 3.  The role of novel biomarkers in childhood idiopathic nephrotic syndrome: a narrative review of published evidence.

Authors:  Samuel N Uwaezuoke
Journal:  Int J Nephrol Renovasc Dis       Date:  2017-06-01

4.  Urinary IgG and α2-macroglobulin are powerful predictors of outcome and responsiveness to steroids and cyclophosphamide in idiopathic focal segmental glomerulosclerosis with nephrotic syndrome.

Authors:  Claudio Bazzi; Virginia Rizza; Daniela Casellato; Gilda Stivali; Gregorio Rachele; Pietro Napodano; Maurizio Gallieni; Giuseppe D'Amico
Journal:  Biomed Res Int       Date:  2013-09-04       Impact factor: 3.411

5.  Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness.

Authors:  Claudio Bazzi; Virginia Rizza; Daniela Casellato; Rafid Tofik; Anna-Lena Berg; Maurizio Gallieni; Giuseppe D'Amico; Omran Bakoush
Journal:  BMC Nephrol       Date:  2014-05-08       Impact factor: 2.388

6.  A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants.

Authors:  Chay Ngee Lim; Constantino Kantaridis; Isabelle Huyghe; Donal Gorman; Stephen Berasi; Gabriele E Sonnenberg
Journal:  Pharmacol Res Perspect       Date:  2021-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.